# Phase 1 Carcinoma, Hepatocellular trials: 67 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 67 trials in phase 1 for Carcinoma, Hepatocellular that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Carcinoma, Hepatocellular trials: 67 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/carcinoma-hepatocellular

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 67
- Recruiting or not yet: 67
- Read on: November 19, 2026

## Trials

The 25 newest of 67, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 6, 2026 | NCT07861425 | Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard... | Acepodia Biotech, Inc. | Phase 1 | Recruiting | Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic, Hepatocellular Carcinoma Non-Resectable | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861425) |
| June 3, 2026 | NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | Huahui Health | Phase 1 | Recruiting | Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Head and Neck Squamous Cell... | 299 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623369) |
| May 19, 2026 | NCT07594964 | To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent... | Shenzhen Xinhe Biomedical | Phase 1 | Recruiting | Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC), Hepatocellular... | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594964) |
| May 13, 2026 | NCT07583316 | A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A\*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors | Corregene Biotechnology Co., Ltd | Phase 1 | Not yet recruiting | Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC) | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583316) |
| May 12, 2026 | NCT07580261 | YMN-A02 for Advanced Primary Hepatocellular Carcinoma. | West China Hospital | Phase 1 | Not yet recruiting | Hepatocellular Carcinoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07580261) |
| April 30, 2026 | NCT07558200 | Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 | Not yet recruiting | Solid Tumors, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07558200) |
| March 25, 2026 | NCT07493044 | An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma | Guangzhou FineImmune Biotechnology Co., LTD. | Phase 1 | Recruiting | Advanced Hepatocellular Carcinoma (HCC), GPC3 Positive Hepatocellular Carcinoma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07493044) |
| February 27, 2026 | NCT07436988 | Affordable Made-in-India Microspheres for Liver Cancer Therapy | Post Graduate Institute of Medical Education and Research, Chandigarh | Phase 1 | Not yet recruiting | Hepatecellular Carcinoma | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07436988) |
| February 19, 2026 | NCT07419841 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | Compass Therapeutics | Phase 1 | Recruiting | Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC) | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07419841) |
| February 6, 2026 | NCT07391839 | MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma. | Suzhou Mednovo Yi Medical Technology Co., Ltd. | Phase 1 | Recruiting | Hepatoma, Unresectable Hepatocellular Carcinoma (HCC) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07391839) |
| February 6, 2026 | NCT07391670 | A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab | AstraZeneca | Phase 1 | Recruiting | Solid Tumours | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07391670) |
| January 29, 2026 | NCT07376707 | A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors | Hefei TG ImmunoPharma Co., Ltd. | Phase 1 | Recruiting | CRC (Colorectal Cancer), Melanoma (Skin Cancer), HCC - Hepatocellular Carcinoma, NSCLC (Non-small Cell Lung Cancer) | 194 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07376707) |
| January 27, 2026 | NCT07369505 | Sapu003 in Advanced mTOR-sensitive Solid Tumors | SAPU NANO (US) LLC | Phase 1 | Recruiting | Breast Cancer Metastatic, Renal Cell Carcinoma (RCC), Neuroendocrine Tumors, Tuberous Sclerosis Complex (TSC)... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07369505) |
| January 23, 2026 | NCT07364357 | A Phase I Study of CREPT-618 in Locally Advanced HCC | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 | Recruiting | Hepatocellular Carcinoma (HCC) | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07364357) |
| January 16, 2026 | NCT07348211 | First in Human Study of SIM0610 in Solid Tumors | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Advanced Solid Tumours, Non-Small Cell Lung Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma... | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07348211) |
| December 10, 2025 | NCT07275073 | JMT106 Injection in the Treatment of Advanced Solid Tumors | Shanghai JMT-Bio Inc. | Phase 1 | Recruiting | Advanced Solid Tumor, Lung Squamous Cell Carcinoma, Hepatocellular Carcinoma | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07275073) |
| November 28, 2025 | NCT07252661 | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors | AccSalus Biosciences, Inc. | Phase 1 | Not yet recruiting | Hepatocellular Carcinoma, Renal Cell Carcinoma, Thyroid Carcinoma, Medullary, Thyroid Carcinoma Primary Differentiated... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07252661) |
| November 24, 2025 | NCT07244835 | A Study of DEG6498 in Participants With Solid Tumors | Degron Therapeutics Co. | Phase 1 | Recruiting | Malignant Neoplasms | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07244835) |
| November 4, 2025 | NCT07224568 | Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors | Seattle Children's Hospital | Phase 1 | Not yet recruiting | Solid Tumor (Excluding CNS), Hepatocellular Carcinoma, Liver Cell Carcinoma, Liposarcoma, Yolk Sac Tumor... | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07224568) |
| September 29, 2025 | NCT07197554 | A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies | SEED Therapeutics, Inc. | Phase 1 | Recruiting | Advanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC), Biliary Tract Cancer (BTC) | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07197554) |
| September 16, 2025 | NCT07176650 | Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY®... | Shanghai Henlius Biotech | Phase 1 | Recruiting | Hepatocellular Carcinoma (HCC) | 246 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07176650) |
| September 10, 2025 | NCT07164313 | A Study of ZW251 in Participants With Advanced Solid Tumors | Zymeworks BC Inc. | Phase 1 | Recruiting | Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07164313) |
| August 29, 2025 | NCT07148050 | Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor... | Seattle Children's Hospital | Phase 1 | Recruiting | Solid Tumor (Excluding CNS), Liver Cell Carcinoma, Malignant Rhabdoid Tumor, Yolk Sac Tumor, Liposarcoma... | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07148050) |
| August 11, 2025 | NCT07116486 | A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma | M.D. Anderson Cancer Center | Phase 1 | Recruiting | Hepatocellular Carcinoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07116486) |
| August 6, 2025 | NCT07106827 | A Study of GV20-0251 in Advanced or Refractory Solid Tumors | West China Hospital | Phase 1 | Recruiting | HCC - Hepatocellular Carcinoma, Cholangiocarcinoma, Melanoma, NSCLC (Non-small Cell Lung Cancer), Pancreatic Ductal... | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07106827) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| West China Hospital | 4 |
| Seattle Children's Hospital | 2 |
| Lion TCR Pte. Ltd. | 2 |
| Second Affiliated Hospital of Guangzhou Medical University | 2 |
| M.D. Anderson Cancer Center | 2 |
| National Cancer Institute (NCI) | 2 |
| Degron Therapeutics Co. | 1 |
| Chinese PLA General Hospital | 1 |
| Myeloid Therapeutics | 1 |
| Guangzhou FineImmune Biotechnology Co., LTD. | 1 |
| University Hospital, Lille | 1 |
| [Alnylam Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/alnylam-pharmaceuticals) | 1 |
| [Exelixis](https://specstream.ai/data/clinical-trials/company/exelixis) | 1 |
| SEED Therapeutics, Inc. | 1 |
| GONGCHU Biotechnology Co., Ltd | 1 |
| [Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.](https://specstream.ai/data/clinical-trials/company/shanghai-fosun-pharmaceutical-industrial-development-co-ltd) | 1 |
| Fudan University | 1 |
| Nammi Therapeutics Inc | 1 |
| [Bayer](https://specstream.ai/data/clinical-trials/company/bayer) | 1 |
| University of Hawaii | 1 |
| [Shanghai Henlius Biotech](https://specstream.ai/data/clinical-trials/company/shanghai-henlius-biotech) | 1 |
| ViroMissile, Inc. | 1 |
| Acepodia Biotech, Inc. | 1 |
| [MacroGenics](https://specstream.ai/data/clinical-trials/company/macrogenics) | 1 |
| Chiome Bioscience Inc. | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 32 |
| United States | 22 |
| Australia | 8 |
| South Korea | 7 |
| Taiwan | 6 |
| Spain | 5 |
| Japan | 5 |
| France | 4 |
| United Kingdom | 4 |
| Italy | 3 |
| Belgium | 3 |
| Canada | 3 |
| Germany | 2 |
| Israel | 2 |
| Poland | 2 |
| Singapore | 2 |
| Austria | 1 |
| New Zealand | 1 |
| Switzerland | 1 |
| Finland | 1 |
| India | 1 |
| Indonesia | 1 |
| Ireland | 1 |
| Portugal | 1 |
| Georgia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Printing companies in the United States](https://specstream.ai/data/businesses/printing-companies/united-states)
- [Ethiopian restaurants in the United States](https://specstream.ai/data/businesses/ethiopian-restaurants/united-states)
- [Wallpaper installers in the United States](https://specstream.ai/data/businesses/wallpaper-installers/united-states)
- [Logging companies in the United States](https://specstream.ai/data/businesses/logging-companies/united-states)
- [Career counseling services in the United States](https://specstream.ai/data/businesses/career-counseling-services/united-states)
- [Retaining wall suppliers in the United States](https://specstream.ai/data/businesses/retaining-wall-suppliers/united-states)
